PolyPid Announces the Initiation of a Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Sternal Wound Infection Post-Cardiac Surgery
Petah Tikva, Israel, February 27, 2020 -- PolyPid Ltd., a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that the first patient has been enrolled and randomized in a Phase 3 clinical trial called SHIELD (Surgical site Hospital acquired Infection prEvention with…
Read more >